The newly formed company, referred to as “New BD,” will continue as a pure-play MedTech leader, building on the momentum from the BD 2025 strategy. This strategy has already positioned BD as a frontrunner in the healthcare industry, targeting long-term growth trends and ensuring sustainable profitability. New BD will focus on categories that are critical to shaping the future of healthcare, leveraging its established market presence and innovation capabilities.
On the other hand, the Biosciences and Diagnostic Solutions business is set to carve its niche as a distinct entity within the Life Sciences Tools and Diagnostics sector. With its robust innovation pipeline and strong market positioning, it is well-poised for growth in vital areas of research and diagnostics.
This separation is expected to bring enhanced operational efficiencies and a sharper strategic focus to both businesses, allowing them to pursue tailored investment strategies and capital allocations that align with their respective market dynamics and growth opportunities.
“Today’s announcement marks an exciting new chapter for BD as we streamline our focus towards areas with high growth potential within the MedTech landscape,” said Tom Polen, Chairman, CEO, and President of BD. “We are confident that this strategic realignment will allow both New BD and the spun-off entity to achieve their full potential, delivering enhanced value to our customers, employees, and shareholders alike.”
The planned separation, set to be completed by fiscal 2026, will involve detailed strategic reviews and is subject to customary regulatory approvals. In the meantime, BD will continue to drive innovation and market expansion in line with its BD 2025 strategy.
